Results 261 to 270 of about 114,558 (301)
Some of the next articles are maybe not open access.
Preclinical Pharmacokinetics and General Toxicology of Iodixanol
Acta Radiologica, 1995To document the safety of iodixanol and to assess its pharmacokinetic properties, extensive tests have been performed. Iodixanol was rapidly excreted, mainly via the kidneys, with a plasma half-life in rats and monkeys of 25 and 76 mins, respectively. The pharmacokinetic data were consistent with an extracelleular distribution of iodixanol.
I F, Heglund +4 more
openaire +2 more sources
Nanotechnology in Preclinical Pharmacokinetics
2020The complex physiological and biochemical processes and intrinsic nature of being hostile against foreign biogenic along with non-biogenic components in higher organisms have made the therapeutic development a time-inefficient cascade with respect to quality, efficiency, and safety.
Santosh Malik +3 more
openaire +1 more source
Preclinical pharmacokinetics and stability of isophosphoramide mustard
Cancer Chemotherapy and Pharmacology, 1994Stability and preclinical pharmacokinetics of isophosphoramide mustard (IPM), an active metabolite of ifosphamide, were investigated using analytical methods developed in this laboratory. For stability evaluation of IPM we used a rapid, high-pressure liquid chromatographic (HPLC) method by which IPM is analyzed directly from aqueous solutions without ...
J J, Zheng, K K, Chan, F, Muggia
openaire +2 more sources
Pharmacology and preclinical pharmacokinetics of peppermint oil
Phytomedicine, 2005The principal pharmacodynamic effect of peppermint oil relevant to the gastrointestinal tract is a dose-related antispasmodic effect on the smooth musculature due to the interference of menthol with the movement of calcium across the cell membrane. The choleretic and antifoaming effects of peppermint oil may play an additional role in medicinal use ...
H G, Grigoleit, P, Grigoleit
openaire +2 more sources
Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics
Clinical Pharmacokinetics, 2018Daclatasvir is a first-in-class, highly selective, hepatitis C virus, non-structural protein 5a polymerase replication complex inhibitor with picomolar potency and broad genotypic coverage in vitro. Daclatasvir undergoes rapid absorption, with a time to reach maximum plasma concentration of 1-2 h and an elimination half-life of ~ 10 to 14 h observed in
Yash Gandhi +5 more
openaire +2 more sources
Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study [PDF]
Acta Obstetricia Et Gynecologica Scandinavica, 2010 AbstractObjective. To determine the impact of physiologic changes of pregnancy on pharmacokinetics of chemotherapeutic agents. Design. A preclinical and a clinical case–control trial. Setting. Institute of Primate Research Nairobi and collaborating hospitals in Belgium, the Netherlands and Czech Republic. Population.
Kristel Van Calsteren +2 more
exaly +7 more sources
Preclinical and clinical pharmacokinetics of pirmenol
The American Journal of Cardiology, 1987Metabolic disposition and pharmacokinetics of pirmenol were studied in laboratory animals and in patients with premature ventricular beats. After intravenous administration, pirmenol pharmacokinetics were adequately characterized by a 2-compartment body model with elimination half-lives of 3 to 4 hours in animals and 6 to 9 hours in patients.
openaire +2 more sources
Preclinical pharmacokinetics of the radiomitigator KZ-41 in rats
Xenobiotica, 2011KZ-41, a quinic acid derivative, significantly reduces mortality in a murine model of hematopoietic acute radiation syndrome. The purpose of this study was to evaluate the systemic pharmacokinetics, elimination, and oral bioavailability of KZ-41 in rats.
Kui, Zeng +4 more
openaire +2 more sources
Quinapril—A Preclinical Review of the Pharmacology, Pharmacokinetics, and Toxicology
Angiology, 1989Quinapril is an orally active, non- peptide, nonsulfhydryl angiotensin- converting enzyme (ACE) inhibitor that acts potently and specifically to interrupt the conversion of angioten sin I to angiotensin II in both plasma and tissue. Quinapril is enzymatically hydrolyzed to a pharmacologically active diacid form quinaprilat. Quinapril is efficacious in
Harvey R. Kaplan +4 more
openaire +2 more sources
[Preclinical pharmacokinetics of pefloxacin].
Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 1995The substance and tablets of pefloxacin mesilate manufactured by the Urals Polytechnical University and the National Research Centre of Antibiotics were studied on rats and dogs with the drug oral administration in single and multiple doses equivalent to the human ones.
K K, Manuĭlov +3 more
openaire +1 more source